Tag: macrogenics

May 28, 2019

8 Small Biotech ETFs

Want to invest in small biotech ETFs? Here we profile eight that life science investors may want to look into.
January 28, 2019

MacroGenics Announces Removal of Partial Clinical Hold on MGD009 Program by FDA

MacroGenics (NASDAQ:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer,...
December 24, 2018

Pharma Outlook 2019: Drug Pricing Dialogue Continues

During this challenging time in healthcare news, our pharma outlook aims to help investors steer through the industry.
April 16, 2018

Aptevo Therapeutics’ Bispecific Antibody APVO436 Shows Robust T-Cell Activation With Minimal Cytokine Release

Aptevo Therapeutics (Nasdaq:APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, today announced the presentation of new data...
March 28, 2018

MacroGenics Announces Pricing of Public Offering of Common Stock

MacroGenics (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of...
February 28, 2018

MacroGenics Provides Update on Corporate Progress and 2017 Financial Results

MacroGenics (NASDAQ:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer,...
January 24, 2018

MacroGenics Announces Continuation of SOPHIA Study of Margetuximab Based on Completion of Interim Futility Analysis

MacroGenics (NASDAQ:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer,...